Small molecules that target the deranged PN in CF (proteostasis regulators) can represent an alternative strategy to circumvent CFTR defect.7, 8, 32, 33, 34 We reported that a combination of two proteostasis regulators, cysteamine, an FDA-approved drug for the treatment of patients affected by cystinosis, and the over-the-counter nutraceutical epigallocatechin-gallate (EGCG) is effective in rescuing a functional F508del-CFTR to the cell surface and in stabilizing the rescued CFTR mutant at the plasma membrane of epithelial cells. The gene discussed is CFTR; the disease is cystinosis.